NICE approves aripiprazole in adolescents

Aripiprazole is also licensed for the treatment of manic episodes in bipolar disorder.
Aripiprazole is also licensed for the treatment of manic episodes in bipolar disorder.

Aripiprazole (Abilify) has been accepted for second-line NHS use in adolescents.

The atypical antipsychotic is recommended as an option for the treatment of schizophrenia in patients aged 15–17 years in whom risperidone is contraindicated, not tolerated or does not provide adequate symptom control.

NICE recommended aripiprazole in these circumstances because its efficacy and price are comparable to those of other alternatives to risperidone available on the NHS, but it is less likely to cause weight gain – a particularly troublesome side-effect for adolescents.

Use of aripiprazole in adults with schizophrenia (18 years and older) was not considered in the appraisal. The NICE clinical guideline on schizophrenia covers the management of schizophrenia in this age group.

View Abilify drug record

NICE guidance on aripiprazole

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more